Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03624920
Recruitment Status : Active, not recruiting
First Posted : August 10, 2018
Last Update Posted : January 22, 2020
Sponsor:
Information provided by (Responsible Party):
Theranexus

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a randomized, placebo-controlled, 3-way cross-over phase IIa trial comparing two dose levels of THN102 to placebo in patients suffering from Parkinson's disease associated with excessive daytime sleepiness.

Condition or disease Intervention/treatment Phase
Parkinson Disease Drug: THN102 Dosage A Drug: THN102 Dosage B Drug: THN102 Dosage C Phase 2

Detailed Description:
The treatment duration is 2 weeks per period. Each treatment period is followed by a one-week washout period.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Complete 3 way-Crossover
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Safety and Efficacy of THN102 in Patients With Parkinson's Disease and Excessive Daytime Sleepiness
Actual Study Start Date : July 12, 2018
Actual Primary Completion Date : December 20, 2019
Estimated Study Completion Date : February 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Placebo Comparator: THN102 Dosage A
THN102 Dosage A is a Placebo
 Drug: THN102 Dosage A
THN102 Dosages A: placebo
Other Name: Placebo
Experimental: THN102 Dosage B
THN102 Dosage B : 200 mg/2 mg THN102 is a combination of modafinil 100mg and flecainide 1 mg daily dosage is 200 mg of modafinil and 2 mg of flecainide
 Drug: THN102 Dosage B
THN102 Dosage B : 200mg/2mg
Other Name: Dosage B
Experimental: THN102 Dosage C
THN102 Dosage C : 200 mg/18 mg THN102 is a combination of modafinil 100mg and flecainide 9 mg daily dosage is 200 mg of modafinil and 18 mg of flecainide
 Drug: THN102 Dosage C
THN102 Dosage C: 200mg/18mg
Other Name: Dosage C


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety Adverse events [ Time Frame: 2 weeks ]
    Number of participants with spontaneously reported treatment-related adverse events


Secondary Outcome Measures :
  1. Efficacy in improving sleepiness (ESS) [ Time Frame: 2 weeks ]
    To quantify the efficacy of THN102 versus placebo in improving sleepiness as assessed. by the decrease of the total score (range 0-24) of the Epworth Sleepiness Scale (ESS).

  2. Efficacy Vigilance [ Time Frame: 2 weeks ]
    To quantify the efficacy of THN102 versus placebo in improving vigilance assessed by the Psychomotor Vigilance Test (PVT). The purpose of the PVT is to measure sustained attention, and give a numerical measure of improvement of vigilance by a decreased number of lapses in attention of the tested subject.

  3. Efficacy Cognition [ Time Frame: 2 weeks ]
    To quantify the efficacy of THN102 versus placebo in improving cognition assessed by the Montreal Cognitive Assessment battery (MoCA). Possible maximum of 30 points. A final total score of 26 and above is considered normal.


Other Outcome Measures:
  1. Plasma concentrations at steady state [ Time Frame: 2 weeks ]
    To determine the trough plasma concentrations of modafinil and flecainide at steady state


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects with a diagnosis of idiopathic Parkinson's disease as defined by the Movement Disorders Society (MDS).
  • Subjects with Hoehn and Yahr scale score ≤ 4.
  • Body mass index > 18 kg/m2 and < 35 kg/m2.
  • Subjects should have a complaint of daytime sleepiness impacting their quality of life and/or daytime functioning (e.g. falling asleep while reading or watching television, while eating or talking with other people).
  • Epworth Sleepiness Scale (ESS) score ≥ 14.

Exclusion Criteria:

  • Subjects with known or with a suspected sleep apnea syndrome or who have any other cause of excessive daytime sleepiness, such as shift work sleep disorder.
  • Psychiatric and neurological disorders (other than Parkinson's disease),
  • Cardiovascular disorders such as - but not limited to
  • Uncontrolled moderate to severe hypertension
  • History or current diagnosis of electrocardiogram (ECG) abnormalities indicating significant risk of safety for patients participating in the study
  • Recent myocardial infarction
  • Stable or unstable angina pectoris
  • Cardiac insufficiency or history of heart failure
  • Previous history of cardiac valvular surgery
  • Subjects with current impulse control disorder.
  • Subjects showing dementia or with MoCA < 23.
  • Subjects with current suicidal risk
  • Current or recent (within one year) history of substance abuse or dependence disorder
  • Other active clinically significant illness
  • Subjects with hepatic or renal impairment
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03624920


Locations
Show Show 34 study locations
Sponsors and Collaborators
Theranexus
Investigators
Layout table for investigator information
Study Chair: Jean-Christophe Corvol, Prof Hôpital La Pitié-Salpêtrière, 75651 Paris, France, Tel. +33 1 42 16 57 66, mail: jean-christophe.corvol@aphp.fr
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Theranexus
ClinicalTrials.gov Identifier: NCT03624920    
Other Study ID Numbers: THN102-202
First Posted: August 10, 2018    Key Record Dates
Last Update Posted: January 22, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Sleepiness
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
 Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Signs and Symptoms